RT Journal Article
SR Electronic
T1 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.119.237990
DO 10.2967/jnumed.119.237990
A1 Kamel Hasan, Olfat
A1 Ravi Kumar, Aravind S
A1 Kong, Grace
A1 Oleinikov, Kira
A1 Ben-Haim, Simona
A1 Grozinsky-Glasberg, Simona
A1 Hicks, Rodney J
YR 2020
UL http://jnm.snmjournals.org/content/early/2020/01/16/jnumed.119.237990.abstract
AB Objectives: Esthesioneuroblastoma (ENB) is rare with limited therapeutic options when unresectable or metastatic; however, expression of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT). We report outcomes of PRRT in ENB from two referral centers. Methods: Using PRRT databases at two European Neuroendocrine Tumour Society Centers of Excellence, case finding was undertaken between 2004-2018 for patients who had PRRT with recurrent/metastatic ENB deemed unsuitable for further conventional therapies. Evaluations of response using a composite reference standard and for survival were performed. Results: Of seven patients, four had partial response, two had disease stabilization and one had early progression. Possible side effects include worsening CSF-leaks. Median progression-free survival was 17 months (range, 0-30), and median overall survival was 32 months (range, 4–53). Conclusion: PRRT shows promising efficacy and moderate survival duration in unresectable locally advanced or metastatic ENB warranting larger cohort studies incorporating measures of quality of life.